MedPath

pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress

Completed
Conditions
Multiple Sclerosis
Interventions
Other: MRI Scan
Registration Number
NCT03028675
Lead Sponsor
NYU Langone Health
Brief Summary

Twenty subjects (10 patients and 10 age-matched control volunteers) will be recruited for this study. MRI scans will take place on a 3T MRI Scanner (Skyra or Prisma, Siemens Medical Solutions) located at The NYU Center for Biomedical Imaging. MRI scans will consist of a 1-hour brain scan for both patients and controls. In the first 6 months of the study, investigators will develop and test a uMT-based APT imaging for brain tissue pH measurement and use a hypercapnia paradigm to validate the tissue pH changes between breathing room air and 5% CO2 (by increasing tissue acidity) inhalation. With implementation of hypercapnia MRI, pH-weighted imaging will be validated for its robustness and reproducibility.

Detailed Description

The contrast agent (Gd-DTPA, Gadavist) will be injected intravenously (IV) in the arm (patients only). The IV will be inserted by qualified medical professional at CBI. This contrast agent will be standard dose in accordance with its FDA approved labeling and dosing. Controls will NOT be administered the contrast agent.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
4
Inclusion Criteria
  • Healthy male or female non-MS control volunteers
Read More
Exclusion Criteria
  • Medically unstable or with cardiac, pulmonary, hematological, renal, or hepatic dysfunction.

  • Current or past DSM-IV diagnosis of major depression, bipolar and psychotic disorders.

  • Contraindications for MRI, including

  • Intracranial clips

  • Metal implants

  • External metallic devices/objects/clips within 10mm of the head

  • Suspected or confirmed metal in the eyes (history of welding or similar activity)

  • Claustrophobia

  • Cardiac pacemaker or pacing wires

  • Pregnancy - Pregnancy tests will be offered to women of childbearing age at no cost to the subject

  • History of moderate to severe head injury, stroke, and seizures.

  • Alcoholism or drug dependency.

  • Renal or liver disease as this may cause concerns related to Gd-DTPA contrast agent.

    • Allergy to the contrast agent Gadolinium
    • Relapses or steroid therapy in patient at or in the month preceding the study
    • Patients only
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Multiple SclerosisMRI Scan-
Healthy VolunteerMRI Scan10 age-matched control volunteers
Primary Outcome Measures
NameTimeMethod
pH measurements20 Minutes

The pH will be estimated based on the calibration methods of quantification of exchange as a function of saturation time (QUEST)32 and its ratiometric analysis (QUESTRA) 33.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

New York University School of Medicine

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath